Physician profile
Rita Pabla
NPI 1942214929
$1,178.69
in general payments reported to CMS, 2019-2025
26 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $62.59 · 2021: $45.67 · 2022: $18.46 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $127.80 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $120.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Akcea Therapeutics, INC. | $78.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.29 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.04 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $63.14 | 2019-2025 | |
| Lilly USA, LLC | $63.06 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $54.60 | 2019-2025 | Repatha, Otezla |
| Dexcom, INC. | $40.22 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $40.18 | 2020-2025 | |
| Exact Sciences Corporation | $33.38 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $32.77 | 2019-2020 | |
| United Therapeutics Corporation | $24.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.30 | 2025 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $20.83 | 2021 | |
| Alk-Abello, INC | $20.55 | 2025 | Neffy |
| Sumitomo Pharma America, INC. | $18.98 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $18.72 | 2025 | Strensiq |
| Jazz Pharmaceuticals INC. | $17.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.61 | 2025 | |
| Scilex Pharmaceuticals INC. | $17.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.17 | 2025 | Rexulti |
| Cranial Technologies, INC | $14.95 | 2019 | |
| Currax Pharmaceuticals LLC | $13.22 | 2019 | |
| Allergan, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Pabla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.